UV Blood Irradiation for Health & Longevity - Quick Reference Sheet

UV Blood Irradiation for Health & Longevity

Created on 07/04/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

A century-old procedure exposing a small share of blood to ultraviolet light to nudge the immune system. Laboratory and historical work suggest it can shift immune activity, but no modern high-quality human trials confirm benefits for health, resilience, or longevity. Risks are manageable but real, and some people should avoid it entirely. An experimental option. (Full Review)

Protocol

Method & Dose
~60 mL treated
Extracorporeal Knott technique; 5–7% of blood volume UV-exposed and reinfused
Course
5–10 sessions
Given as a course, sometimes with occasional maintenance sessions
Frequency
Daily to weekly
Spacing depends on the clinic and indication
Time to effect
Acute infection
24–72 hrs
Historical case reports only
Wellness / immune support
No reliable timeline
Not established for these goals
Subjective benefit
Over a course
Typically judged across several sessions

Benefits

Contraindications
  • Porphyria (absolute)
  • Active hemolytic anemia (absolute)
  • Pregnancy (absolute)
  • G6PD deficiency
  • Photosensitivity disorders (e.g., photosensitive lupus)
  • Significant bleeding or clotting disorders
  • Transplant recipients on immunosuppression
  • Strong photosensitizing medication
Key Interactions
  • Photosensitizing drugs (doxycycline, ciprofloxacin, amiodarone, hydrochlorothiazide, chlorpromazine, isotretinoin)
  • Photosensitizing NSAIDs (piroxicam, ketoprofen)
  • High-dose antioxidants (vitamin C, vitamin E, glutathione, NAC)
  • Photosensitizing botanicals (St. John's wort, dong quai)
  • Ozone and other oxidative therapies
  • Immunosuppressive therapy

Risk & Side Effects

  • High:
  • Medium:
  • Low: Hemolysis & oxidative blood damage, IV access & procedural complications, pro-oxidant / free-radical stress (conflicted)
  • Speculative: Theoretical carcinogenic / DNA-damage risk, photosensitivity & Herxheimer-type reactions, immune dysregulation / autoimmune flare

Monitoring

Marker Target Why
Complete Blood Count (hemoglobin) ~13.5–15 g/dL (men), ~12.5–14 g/dL (women) Detect anemia or red-cell loss and track white-cell shifts
Haptoglobin ~50–150 mg/dL Low levels flag red-cell breakdown (hemolysis) from oxidative dosing
Lactate Dehydrogenase (LDH) ~140–200 U/L Rises with cell / red-cell damage
hs-CRP < 1.0 mg/L Track systemic inflammation response over a course
Erythrocyte Sedimentation Rate (ESR) < 10–15 mm/hr Secondary, slower marker of inflammation
G6PD activity Within lab reference Screen for deficiency that raises hemolysis risk

Cadence: Baseline before starting; recheck after the first session or two, again at the end of a course (~4–8 weeks), then every 6–12 months if maintenance continues

Qualitative Assessment

  • Energy levels and daytime fatigue
  • Frequency and duration of minor infections
  • General sense of wellbeing and recovery
  • Any post-session chills, malaise, or light sensitivity